Thailand’s Ministry of Public Health announced the progress of domestic COVID-19 vaccine development, as follows:
– The first mRNA vaccine developed by Chulalongkorn University researchers is entering the third phase of a clinical trial in 2023. After FDA approval, the vaccine is expected to be available in 2024.
– Baiya SARS-CoV2-VAX vaccine, a COVID-19 plant-based vaccine, initiated by Baiya Phytopharm Co., Ltd. and Chulalongkorn University, has been successfully tested in the first phase of a clinical trial. The formula of the vaccine is currently being adjusted. The third phase will start by the beginning of 2023 before being registered in 2024.
– The inactivated NDV-HXP-S vaccine, manufactured by the Government Pharmaceutical Organization of Thailand, which is coordinating with the PATH Center for Vaccine Innovation and Access, U.S.A., is going to conduct the third phase of a clinical trial by the end of this year (2022) and be registered in 2023.
Producing the homegrown vaccines will make it possible to achieve self-sufficiency, increase collaboration between organizations, and boost national competency in COVID-19 vaccine manufacturing. (PRD)
 |
 |
 |
